Afry AB (0QUU)
London Exchange · UK · prices in SEK · close of 22 Oct 2026
Key indicators
| Last close | SEK 121.75 |
|---|---|
| 52-week range | 98.00 – 173.50 |
| Return, 1 month / 3 months | +21.0% / +20.9% |
| Return, 1 year / 3 years | −24.2% / +13.2% |
| Trend | Uptrend |
| RSI (14) | 76 |
| Volatility (1 year) | 29.2% |
| Worst drawdown (1 year) | -39.3% |
| Average daily value traded | 1.28M SEK |
| Dividend yield | 4.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Afry is an engineering, design and advisory company based in Sweden. It provides consulting services across infrastructure, industry, energy and digitalisation, helping clients plan, design and improve projects and operations. Its customers include companies, public authorities and organisations in sectors such as transport, power, manufacturing and construction. The firm combines technical expertise with advisory work, offering services that range from early studies and design to project management and support during operation.
On this site Afry AB appears as a stock on the London Exchange (UK), code 0QUU, with prices in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Afry AB (0QUU) trades on the London Exchange in UK. It last closed at SEK 121.75 on 22 October 2026.
Its price-based Market X-Ray is 48 out of 100 (a weak price profile), ranking 2,174 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 24.2% and over the last three months it rose 20.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 39 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 6.3% | ||
| From 52-week high | -29.4% | ||
| Momentum | 48 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 20.9% | ||
| 6-month return | -1.7% | ||
| 12-month return, skipping the last month | -37.4% | ||
| Stability (higher is calmer) | 48 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 29.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -39.3% | ||
| Liquidity | 55 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.28M SEK | ||
| Zero-volume days | 8.3% | ||
| Income | 58 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.9% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +16.2% |
|---|---|
| 1 month | +21.0% |
| 3 months | +20.9% |
| 6 months | −1.7% |
| 1 year | −24.2% |
| 3 years | +13.2% |
| 5 years | −48.6% |
Signals
| 50-day / 200-day average | 103.30 / 114.58 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 21.49 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Apr 2026 | SEK 6.0000 |
| 25 Apr 2025 | SEK 6.0000 |
| 24 Apr 2024 | SEK 5.5000 |
| 28 Apr 2023 | SEK 5.5000 |
| 29 Apr 2022 | SEK 5.5000 |
| 4 Jun 2021 | SEK 5.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.